Case-control studies reporting on risk factors for emergence of antimicrobial resistance: Bias associated with the selection of the control group

Microbial Drug Resistance

Volumn 16, Issue 4, 2010, Pages 303-308

  Rafailidis, Petros I ^a,b   Bliziotis, Ioannis A ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; COTRIMOXAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OXACILLIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; COMMUNITY; DRUG POTENTIATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IN VITRO STUDY; NURSING HOME; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; WARD;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; CONTROL GROUPS; DRUG RESISTANCE, MICROBIAL; HUMANS; RISK FACTORS; SELECTION BIAS;

BACTERIA (MICROORGANISMS);

EID: 78650096655     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2009.0134     Document Type: Article

References (24)

1. Abbo, A., S. Navon-Venezia, O. Hammer-Muntz, T. Krichali, Y. Siegman-Igra, and Y. Carmeli. 2005. Multidrugresistant Acinetobacter baumannii. Emerg. Infect. Dis. 11:22-29.
2. Behar, P.R., P.J. Teixeira, J.M. Fachel, and A.C. Kalil. 2008. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J. Hosp. Infect. 68:123-129.
3. Byers, K.E., A.M. Anglim, C.J. Anneski, T.P. Germanson, H.S. Gold, L.J. Durbin, B.M. Simonton, and B.M. Farr. 2001. A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control. Infect. Control Hosp. Epidemiol. 22:140-147.
4. Cao, B., H. Wang, H. Sun, Y. Zhu, and M. Chen. 2004. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J. Hosp. Infect. 57:112-118.
5. Carmeli, Y., M.H. Samore, and C. Huskins. 1999. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: A metaanalysis. Arch. Intern. Med. 159:2461-2468.
6. Clinical and Laboratory Standards Institute. 2007. M100-S17, Performance Standards for Antimicrobial Susceptibility Testing. Seventeenth Informational Supplement. Wayne, PA.
7. Crnich, C.J., N. Safdar, J. Robinson, and D. Zimmerman. 2007. Longitudinal trends in antibiotic resistance in US nursing homes, 2000-2004. Infect. Control Hosp. Epidemiol. 28:1006-1008.
8. DAgata, E.M., M.A. Cataldo, R. Cauda, and E. Tacconelli. 2006. The importance of addressing multidrug resistance and not assuming single-drug resistance in case-control studies. Infect. Control Hosp. Epidemiol. 27:670-674.
9. Furtado, G.H., R.E. Mendes, A.C. Pignatari, S.B. Wey, and E.A. Medeiros. 2006. Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies. Am. J. Infect. Control 34:447-451.
10. Hachem, R.Y., R.F. Chemaly, C.A. Ahmar, Y. Jiang, M.R. Boktour, G.A. Rjaili, G.P. Bodey, and I.I. Raad. 2007. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob. Agents Chemother. 51:1905-1911.
11. Harris, A.D., M.H. Samore, M. Lipsitch, K.S. Kaye, E. Perencevich, and Y. Carmeli. 2002. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin. Infect. Dis. 34:1558-1563.
12. Kaye, K.S., A.D. Harris, M. Samore, and Y. Carmeli. 2005. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect. Control Hosp. Epidemiol. 26:346-351.
13. Kaye, K.S., J.J. Engemann, E. Mozaffari, and Y. Carmeli. 2004. Reference group choice and antibiotic resistance outcomes. Emerg. Infect. Dis. 10:1125-1128.
14. Livermore, D.M., M. Struelens, J. Amorim, F. Baquero, J. Bille, R. Canton, S. Henning, S. Gatermann, A. Marchese, H. Mittermayer, C. Nonhoff, K.J. Oakton, F. Praplan, H. Ramos, G.C. Schito, J. Van Eldere, J. Verhaegen, J. Verhoef, and M.R. Visser. 2002. Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J. Antimicrob. Chemother. 49:289-300.
15. Livermore, D.M., R. Canton, M. Gniadkowski, P. Nordmann, G.M. Rossolini, G. Arlet, J. Ayala, T.M. Coque, I. Kern-Zdanowicz, F. Luzzaro, L. Poirel, and N. Woodford. 2007. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59:165-174.
16. Lodise, T.P., C.D. Miller, J. Graves, J.P. Furuno, J.C. McGregor, B. Lomaestro, E. Graffunder, and L.A. McNutt. 2007. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob. Agents Chemother. 51:417-422. (Pubitemid 46185255)
17. Mandell, L.A., R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, N.C. Dean, S.F. Dowell, T.M. File, Jr., D.M. Musher, M.S. Niederman, A. Torres, C.G. Whitney, and Infectious Diseases Society of America; American Thoracic Society. 2007. Infectious Diseases Society of America=American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44 Suppl 2:S27-S72.
18. McNeil, S.A., P.N. Malani, C.E. Chenoweth, R.J. Fontana, J.C. Magee, J.D. Punch, M.L. Mackin, and C.A. Kauffman. 2006. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin. Infect. Dis. 42:195-203.
19. Oxford Centre for Evidence-Based Medicine. Levels of Evidence. Headington, Oxford, United Kingdom. Available at www.cebm.net=?o1025, accessed March 20, 2010. 2009. (Online.)
20. Safdar, N., and D.G. Maki. 2002. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med. 136:834-844.
21. Schulz, K.F., and D.A. Grimes. 2002. Case-control studies: research in reverse. Lancet 359:431-434.
22. Sunenshine, R.H., M.O. Wright, L.L. Maragakis, A.D. Harris, X. Song, J. Hebden, S.E. Cosgrove, A. Anderson, J. Carnell, D.B. Jernigan, D.G. Kleinbaum, T.M. Perl, H.C. Standiford, and A. Srinivasan. 2007. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis. 13:97-103.
23. Tokars, J.I., S. Satake, D. Rimland, L. Carson, E.R. Miller, E. Killum, R.L. Sinkowitz-Cochran, M.J. Arduino, F.C. Tenover, B. Marston, and W.R. Jarvis. 1999. The prevalence of colonization with vancomycin-resistant Enterococcus at a veterans affairs institution. Infect. Control Hosp. Epidemiol. 20:171-175.
24. Willems, R.J., J. Top, M. van Santen, D.A. Robinson, T.M. Coque, F. Baquero, H. Grundmann, and M.J. Bonten. 2005. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg. Infect. Dis. 11:821-828.